Physician profile
Joseph T Nezgoda
NPI 1861643629
$600,351.58
in general payments reported to CMS, 2019-2025
43 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $36K · 2021: $26K · 2022: $109K · 2023: $74K · 2024: $109K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Honoraria: $47K · Travel and Lodging: $36K · Consulting Fee: $20K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,328.00 |
| Honoraria | $47,225.00 |
| Travel and Lodging | $35,630.22 |
| Consulting Fee | $19,552.00 |
| Food and Beverage | $13,465.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,938.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $299,902.12 | 2019-2025 | Vabysmo, Susvimo |
| Novartis Pharmaceuticals Corporation | $108,326.95 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $66,084.89 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $54,639.35 | 2023-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $27,498.44 | 2020-2025 | Acthar |
| Dutch Ophthalmic, USA | $10,208.54 | 2019-2023 | Eva, Combined Machine, Tissueblue |
| Allergan, INC. | $9,856.97 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $5,095.27 | 2019 | |
| Abbvie INC. | $2,650.96 | 2022-2025 | |
| Astellas Pharma US INC | $2,625.87 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $2,226.74 | 2020-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $2,055.71 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $771.47 | 2019-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $742.88 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $720.85 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $696.49 | 2021-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $532.68 | 2019-2022 | |
| Harrow Eye, LLC | $474.49 | 2024-2025 | Iheezo, Vevye |
| Johnson & Johnson Surgical Vision, INC. | $380.72 | 2021-2024 | Tecnis Iol |
| Ocular Therapeutix, INC. | $370.32 | 2021-2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $350.96 | 2021-2022 | |
| New World Medical,INC. | $340.60 | 2021-2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Carl Zeiss Meditec USA, INC. | $340.10 | 2023-2025 | Quatera 700 |
| Bausch & Lomb Americas INC. | $308.05 | 2022-2025 | Lotemax Sm, Xipere, Visudyne |
| Glaukos Corporation | $265.32 | 2019 | |
| Heidelberg Engineering, INC. | $260.77 | 2019-2025 | Spectralis |
| Biotissue Holdings INC. | $258.95 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $257.93 | 2022-2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Aerie Pharmaceuticals, INC. | $240.23 | 2021 | |
| Coherus Oncology, INC. | $239.34 | 2022-2023 | |
| Omeros Corporation | $234.26 | 2019-2021 | |
| Alcon Vision LLC | $214.08 | 2021-2024 | Constellation |
| Sight Sciences, INC. | $212.01 | 2019 | |
| Astellas Pharma Global Development | $200.49 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $198.75 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $141.47 | 2021-2024 | Oxervate |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Ivantis, INC | $99.19 | 2020 | |
| Oyster Point Pharma, INC. | $97.57 | 2022 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $30.08 | 2025 | |
| Genentech, INC. | $18.30 | 2019 | |
| Shire North American Group INC | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nezgoda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.